MergerApr 30, 2026, 07:47 AM
BRNS Q1 Net Loss $(5.5M); Clywedog Merger Progresses
AI Summary
Barinthus Biotherapeutics plc reported a net loss of $(5.5) million for Q1 2026, a significant improvement from $(19.7) million in Q1 2025. The company also provided updates on its merger agreement with Clywedog Therapeutics, Inc., where Barinthus will become a wholly-owned subsidiary of Topco, and Clywedog will merge into Topco. Barinthus shareholders will receive Topco common stock, and a potential $27.0 million self-tender offer for Topco shares may precede the merger.
Key Highlights
- Merger agreement with Clywedog Therapeutics progressing, expected to close by September 30, 2026.
- BRNS shareholders to receive 0.1 to 0.166667 shares of Topco Common Stock per share.
- Q1 2026 net loss significantly improved to $(5.5) million from $(19.7) million YoY.
- Research and development expenses decreased to $3.6 million from $8.3 million YoY.
- General and administrative expenses decreased to $2.5 million from $12.6 million YoY.
- Cash and cash equivalents stood at $65.9 million as of March 31, 2026.
- Net cash used in operating activities improved to $(3.4) million from $(14.9) million YoY.
- Company is strategically focusing on immunology and inflammation, deprioritizing other programs.
Price Impact
More from BRNS